JP2005272348A - Antihypertensive composition - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a novel use of an aqueous extract of Zea mays LINNE. <P>SOLUTION: The aqueous extract of Zea mays LINNE is used as an active ingredient of an antihypertensive composition. A health food containing the aqueous extract of Zea mays LINNE is used for preventing, treating or ameliorating hypertension. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  The present invention relates to an antihypertensive composition used for the prevention, treatment or amelioration of hypertension, comprising an aqueous extract of purple corn as an active ingredient. Furthermore, the present invention relates to a health food used for the prevention or amelioration of hypertension, which contains an effective amount of an aqueous extract of purple corn.

  Purple corn [Zea mays LINNE] has been conventionally used as a raw material for extracting purple corn pigment. Such purple corn pigment is widely used for coloring foods such as soft drinks, jelly, and koji as anthocyanin pigments, and is known to exhibit acidic red, neutral neutral dark purple blue, and alkaline dark green. ing.

In recent years, anthocyanin pigments are not only useful as colorants, but also have various physiological activities other than coloration, specifically blood cholesterol lowering action (Non-patent Document 1), antioxidant action (Non-patent document 2), anti-mutagenicity (non-patent document 3), and anti-tumor activity (non-patent document 4) have been reported.
Agric. Biol. Chem., 54 (1), 171-175, 1990 J. Agric. Food Chem. 50, 6172-6181, 2002 Foods & Food Ingredients Journal of Japan (FFI Reports), No.192 (separate volume), pp. 77, 2001. Cancer Letters 171, 17-25. 2001

  The present invention provides an antihypertensive composition capable of significantly suppressing the onset of hypertension by suppressing the increase in blood pressure for those who tend to develop hypertension (or those who tend to develop hypertension). For the purpose. More specifically, an object of the present invention is to provide an antihypertensive composition that has an excellent blood pressure elevation-inhibiting action, is highly safe, and can be continuously taken as a health food.

  The inventors of the present invention have made extensive studies to solve the above-described problems. As a result, an aqueous extract of purple corn was added to an animal (rat) (naturally hypertensive rat) constructed so as to spontaneously develop hypertension. It was found that the occurrence of hypertension is significantly suppressed by oral administration, and that even if it is continuously administered, the safety is extremely high without adverse effects. We were convinced that it can be effectively used for prevention and improvement of The present invention has been completed based on such findings.

That is, the present invention has the following configuration:
Item 1: An antihypertensive composition comprising an aqueous extract of purple corn as an active ingredient.
Item 2: The antihypertensive composition according to Item 1, which is used by adding to food.
Item 3: A health food containing an aqueous extract of purple corn used for the prevention, treatment or amelioration of hypertension.

  Hereinafter, the present invention will be described in more detail.

  The antihypertensive composition of the present invention comprises an aqueous extract of purple corn [Zea mays LINNE] as an active ingredient.

  Purple corn used as a raw material for the aqueous extract is cultivated in the mountains of South America, and it is the original source of dark purple corn that has been used for food by natives since ancient times. In Japan, purple corn pigment obtained by extracting from purple seeds and cores of purple corn is used as anthocyanin pigment for coloring foods such as soft drinks, jelly, and strawberries.

  The method for preparing an aqueous extract of purple corn is not particularly limited. Preferably, as an extraction solvent, for example, an inorganic acid such as hydrochloric acid, sulfuric acid or phosphoric acid, or an organic acid such as citric acid or malic acid adjusted to a pH range of about 1 to 4 is used under such acidic conditions. And a method of immersing purple corn under low temperature, warming or boiling conditions for about 4 to 12 hours, for example, overnight. At this time, the purple corn used for the extraction is preferably purple seeds and cores of purple corn, which may be (raw) or cut or crushed to an appropriate size, or may be dried. (As-is shape, coarse powder, shredded product) may be used. The extract obtained by soaking may be used as it is, but if necessary, after removing solids by filtration, coprecipitation or centrifugation, it can be concentrated as it is, or it can be subjected to purification treatment. it can.

  The “purple corn aqueous extract” as used in the present invention includes not only the aqueous extract directly obtained from the above-described extraction process, but also all the processed products obtained by further purification after the extraction process.

  Although it does not restrict | limit especially as said extraction solvent, Water, a lower alcohol, or a mixture thereof can be mentioned. Examples of lower alcohols include C1-C4 lower alcohols such as methanol, ethanol, propanol, isopropyl alcohol, and butanol. The lower alcohol is preferably ethanol. The extraction solvent is preferably water or hydrous alcohol (particularly hydrous ethanol), more preferably water. In addition, when using a hydrous alcohol as a water-soluble solvent, it is preferable that the amount of alcohol contained in it is more than 0 volume% and 80 volume% or less.

  In addition, as a method for extraction, a generally used method can be adopted, in addition to the above-described immersion method (stationary); a method of performing extraction with stirring under low temperature, warming or boiling conditions; or a percolation method, etc. Can also be used.

  The aqueous extract of purple corn thus obtained (hereinafter, the aqueous extract obtained directly from the extraction process is also referred to as “purified corn extract processed product”) can be further subjected to an adsorption process as a purification process. .

  Here, the adsorption treatment can be carried out in accordance with an ordinary method, for example, adsorption treatment with activated carbon, silica gel, porous ceramic or the like; styrene-based duolite S-861 (trademark Duolite, USA manufactured by Diamond Shamrock, the same shall apply hereinafter) , Duolite S-862, Duolite S-863 or Duolite S-866; aromatic Sepa beads SP70 (trademark, manufactured by Mitsubishi Chemical Corporation, the same shall apply hereinafter), Sepa beads SP700, Sepa beads SP825; Diaion HP10 (trademark) Manufactured by Mitsubishi Chemical Corporation, the same shall apply hereinafter), Diaion HP20, Diaion HP21, Diaion HP40, and Diaion HP50; or Amberlite XAD-4 (trademark, manufactured by Organo, the same shall apply hereinafter), Amberlite XAD-7 An adsorption treatment using a synthetic adsorption resin such as Amberlite XAD-2000 can be mentioned. Next, the aqueous extract as the active ingredient of the present invention adsorbed and supported on the resin carrier can be recovered by washing the resin carrier with an appropriate solvent such as hydrous alcohol. As the hydrous alcohol, those containing usually 10 to 60% by volume, preferably 25 to 45% by volume of ethanol can be suitably exemplified.

  The purple corn aqueous extract adsorption treatment solution thus obtained is subjected to adsorption treatment again or subjected to various treatments such as ion exchange treatment, membrane separation treatment, extraction treatment or pH adjustment treatment (acid treatment). The These processes may be performed in combination of one or more kinds, and can also be performed by repeatedly performing the same process under the same or different conditions.

  Examples of the adsorption process include the processes described above.

  The ion exchange treatment is not particularly limited, and a cation exchange treatment or an anion exchange treatment can be performed according to a conventional method using a conventional resin. Examples of cation exchange resins include, but are not limited to, Diaion SK 1B (trademark, manufactured by Mitsubishi Chemical Corporation, the same shall apply hereinafter), Diaion SK 102, Diaion SK 116, Diaion PK 208, Diaion WK10, Diaion WK20 and other anion exchange resins are not limited, but may be Diaion SA 10A (trademark, manufactured by Mitsubishi Chemical Corporation, the same shall apply hereinafter), Diaion SA 12A, Diaion SA 20A, Diaion PA 306, Diaion Examples include WA 10 and Diaion WA 20.

  The membrane separation method referred to in the present invention broadly means a filtration method using a membrane. For example, functionalities such as a membrane filter (MF) membrane, an ultrafiltration (UF) membrane, a reverse osmosis membrane, and an electrodialysis membrane. Examples thereof include a filtration treatment using a polymer membrane. In addition to membrane separation methods such as ultrafiltration and reverse osmosis using these membranes, dialysis using concentration gradients by ion-selective membranes, and using an ion-exchange membrane as a diaphragm to apply voltage Dialysis methods are known. Industrially, a membrane separation method by a reverse osmosis membrane method is preferable. Examples of the membrane material used in the membrane separation method include cellulose, cellulose di-acetate or tri-acetate, polyamide, polysulfone, polystyrene, polyimide, polyacrylonitrile, etc. be able to.

In the membrane separation method of the present invention, a treatment method in which a polymer compound is separated and removed using a membrane having a fractional molecular weight in the range of, for example, 10 ⁴ to 10 ⁶ and a fractional molecular weight of about 2000 to 4000, preferably 3000 A processing method of separating and removing low molecular weight compounds using a membrane of a degree is included. Specifically, the former method includes NTU-3150 membrane, NTU-3250 membrane, NTU-3550 membrane, NTU-3800 UF membrane (above, manufactured by Nitto Denko); Cefilt-UF (manufactured by NGK); AHP-2013 membrane, Examples of the ultrafiltration (UF) membrane treatment using AHP-3013 membrane, AHP-1010 membrane (manufactured by Asahi Kasei); etc., and the latter method are specifically NTR-7250 membrane, NTR- 7410 membrane, NTR-7430 membrane, NTR-7450 membrane (above, manufactured by Nitto Denko), AIP-3013 membrane, ACP-3013 membrane, ACP-2013 membrane, AIP-2013 membrane, AIO-1010 membrane (above, made by Asahi Kasei) For example, a reverse osmosis membrane (nanofiltration membrane, about 3000 molecular weight cut off) treatment using a membrane such as These may be carried out singly or in combination of two.

  In the present invention, the extraction treatment is not particularly limited, but a method of bringing carbon dioxide gas, ethylene, propane, etc. into contact with the purple corn pigment extract adsorption treatment solution in a closed system device at a temperature and pressure above the critical point. Can be mentioned.

  The pH adjustment treatment (acid treatment) can be carried out by adjusting the adsorption treatment solution of purple corn aqueous extract or the treatment solution subjected to the above-mentioned various treatments to pH 1 to 4 and exposing them to acidic conditions. The acid treatment is preferably performed under the condition of pH 1.5-2. Specifically, the acid treatment can be easily carried out by adding and adding an acid to the treatment liquid. Such an acid is not particularly limited as long as it is an acid usually used as a food additive, and can be arbitrarily selected and used. Examples thereof include organic acids such as citric acid, acetic acid, malic acid and lactic acid, or inorganic acids such as sulfuric acid, hydrochloric acid, phosphoric acid and nitric acid. The acid treatment using an inorganic acid usually used as a food additive is preferable.

  The temperature conditions for performing such acid treatment are not particularly limited, and can be appropriately selected and used usually in the range of 5 to 100 ° C. For example, the range of 20-100 degreeC and 40-100 degreeC can be illustrated. The acid treatment time is not particularly limited, and can be appropriately selected from the range of usually 1 to 300 minutes. In general, a shorter treatment time is sufficient if the treatment is performed at a high temperature. For example, in the case of treatment at 40 to 100 ° C., the treatment time can be selected from the range of 5 to 60 minutes. At this time, the treatment liquid is not particularly limited even if it is not stirred.

  Although a preferable treatment method is not particularly limited, it is a method in which an adsorption treatment is performed on the purple corn extract and a membrane separation treatment is performed after the desorption treatment solution. Further, if necessary, an ion exchange treatment (preferably an anion exchange resin treatment) can be performed after the desorption treatment. Here, the membrane separation treatment is preferably reverse osmosis membrane treatment or ultrafiltration membrane treatment, and more preferably reverse osmosis membrane treatment. The membrane separation treatment is preferably performed using a membrane having a molecular weight cut-off of 2000 to 4000, preferably around 3000.

  As shown in the test examples described later, the present inventors obtained anti-hypertension which is the object of the present invention when the purple corn aqueous extract of the present invention obtained by the above method is orally administered to spontaneously hypertensive rats. It was confirmed that the action (blood pressure increase inhibiting action) was effectively exhibited. Furthermore, the purple corn aqueous extract was confirmed to be extremely safe without adversely affecting the rat even when continuously administered orally. Therefore, the purple corn aqueous extract of the present invention is used as an antihypertensive agent, an antihypertensive agent, or an antihypertensive agent for subjects such as humans who tend to develop hypertension (or hypertension). It can be used effectively as a health food having such an effect.

  Therefore, according to the present invention, an antihypertensive composition comprising a purple corn aqueous extract as an active ingredient can be provided.

  Such purple corn aqueous extract can be in the form of a solution (emulsion, solution, syrup, etc.) dissolved or dispersed in water, alcohol (eg, ethanol) or other solvent, or in a solid state prepared and molded by a known method. Various preparations (food compositions [for example, supplements], pharmaceutical compositions or quasi-drug compositions, such as powders, powders, granules, tablets, pills, etc.) Thing).

  In addition to the purple corn aqueous extract, the preparation may contain a food sanitation or pharmaceutically acceptable carrier or additive depending on the product form. For example, excipients for preparing solid state formulations include lactose, sucrose, glucose, corn starch, gelatin, starch, dextrin, calcium phosphate, calcium carbonate, synthetic and natural aluminum silicate, magnesium oxide, dry water Examples include aluminum oxide, magnesium stearate, sodium bicarbonate, and dry yeast. In addition, examples of excipients for preparing a preparation in a solution state include water, glycerin, propylene glycol, simple syrup, ethanol, ethylene glycol, polyethylene glycol, sorbitol and the like. In addition, these preparations include a stabilizer such as citric acid, phosphoric acid, malic acid or salts thereof; a sweetener such as sucralose or acesulfame potassium; a sweetener such as sucrose or fructose; an alcohol, Preservatives such as glycerin; may be mixed with conventional additives such as demulcents, diluents, buffering agents, flavoring agents and coloring agents, and in conventional or other suitable manners, powders, tablets, It can be produced in a form for oral administration such as emulsion, capsule, granule, chewable, liquid, syrup and the like.

  In addition, the above-mentioned purple corn aqueous extract suppresses an increase in blood pressure, prevents the development of hypertension in subjects including humans who tend to develop hypertension (or tend to develop hypertension), or It is also useful as an active ingredient in health foods used for the purpose of improving hypertension.

  Here, the health food means food with the purpose of health, health maintenance and promotion in a more positive sense than normal food. The purple corn aqueous extract of the present invention can be added to a general food (in other words, used as one of raw materials) to prepare a health food for the prevention, treatment or improvement of hypertension. Can be used.

  For example, food is not particularly limited, but (1) milk drink, lactic acid bacteria drink, soft drink with fruit juice, soft drink, carbonated drink, fruit juice drink, vegetable drink, vegetable / fruit drink, alcoholic drink, powdered drink, coffee drink Drinks such as tea drinks and tea drinks; (2) custard pudding, milk pudding, souffle pudding, puddings with fruit juice, etc .; desserts such as jelly, bavaroa and yogurt; (3) ice cream, ice milk, lacto ice , Milk ice cream, ice cream and soft ice cream with ice cream, ice candy, sherbet, ice confectionery, etc .; (4) gums such as chewing gum and bubble gum (board gum, sugar-coated grain gum); (5) marble chocolate In addition to coating chocolate such as strawberry chocolate, blueberry chocolate and melon chocolate (6) Hard candy (including bonbon, butterball, marble, etc.), soft candy (including caramel, nougat, gummy candy, marshmallow, etc.), drop, toffee (7) Baked confectionery such as hard biscuits, cookies, rice crackers, rice crackers; (The above (2) to (7) are collectively referred to as confectionery); fruit wine such as red wine, liqueur, Chuhai, Examples include alcohols such as carbonated alcoholic beverages.

  Among them, from the viewpoint of taking continuously, confectionery such as bread, candy and tablet confectionery, other solid products, liquid products such as soft drinks and nutritional beverages, and semi-solid products such as jelly are preferably exemplified. Can do.

  The dose of the purple corn aqueous extract of the present invention is preferably used in the range of 400 to 4000 mg per day for an adult weighing 60 kg, for example.

  However, the dosage may vary depending on various factors such as the health status of the person taking the purple corn aqueous extract, the mode of administration and the combination with other agents. In addition, the ratio of the purple corn aqueous extract contained in the antihypertensive composition or the health food of the present invention per day of these compositions (including food composition, pharmaceutical composition, quasi-drug composition) Can be appropriately set and adjusted based on the above doses.

  Since the purple corn aqueous extract according to the present invention is contained in a large amount of purple corn seeds that have been eaten from the beginning and is used as a food additive, it prevents, treats or improves hypertension. It has the feature that it can be used safely and effectively as an active ingredient of the intended drug, quasi-drug or food and can be produced economically.

  According to the composition comprising the purple corn aqueous extract of the present invention as an active ingredient, it is based on the action of the purple corn aqueous extract for those who tend to develop hypertension or those who tend to develop hypertension. Thus, an effect of suppressing an increase in blood pressure, an effect of suppressing the onset of hypertension, or an effect of improving hypertension can be exhibited. Therefore, the composition of the present invention can be effectively used as an antihypertensive composition as a pharmaceutical product, quasi drug or health food.

  In the following, preparation examples, test examples and examples are described in order to clarify the constitution and effects of the present invention. However, the present invention is not affected by these examples.

Preparation Example 1

  10 kg of purple corn dried product (core and seeds) was put into a mixed solution (pH 2.3) of 100 L of water and 450 g of sulfuric acid, and left to stand overnight at room temperature (extraction treatment). After extraction processing, filter aid (Radiolite 700, Showa Chemical Industry Co., Ltd.) is mixed at a ratio of 2% to the liquid solid-liquid separated by 60 mesh wire mesh, filtered, and purple corn crude extract (purple corn extraction) Processed product) About 100 L was obtained. This crude extract was passed through 10 L of adsorption resin (styrene vinyl benzene copolymer: Diaion HP20, manufactured by Mitsubishi Chemical Corporation) under the conditions of SV = 1 and temperature 20 ° C., and the resin was added 30 L (SV = 1). Further, 15 L of 30 v / v% ethanol / 0.2 wt / v% citric acid aqueous solution was passed through the resin (SV = 1, temperature 20 ° C.), and the desorbed solution was recovered. The obtained detachment liquid was concentrated under reduced pressure at 40 ° C. or less to obtain a purple corn extract.

  This purple corn extract was then passed through 10 L of adsorption resin Sepa beads SP207 (Mitsubishi Chemical Corporation) under the conditions of SV = 1, temperature 20 ° C., and the resin was added with 30 L of water (SV = 1), Subsequently, it was washed with 10 L (SV = 1) of 15 v / v% ethanol / 0.2 wt / v% citric acid aqueous solution. Furthermore, 20 L of 25 v / v% ethanol / 0.2 wt / v% citric acid aqueous solution was passed through the resin (SV = 1, temperature 20 ° C.), and the desorbed solution was recovered. The desorbed liquid was concentrated under reduced pressure at 40 ° C. or lower and then spray-dried to obtain 70 g of a powdery dark red purple corn extract. The powder contained 18.5% cyanidin 3-glucoside.

Test example 1

Effect of purple corn extract on blood pressure Purple corn extract is orally administered to 6-week-old spontaneously hypertensive rats twice a day for 5 weeks, and suppresses blood pressure increase, mainly indicating changes in systolic blood pressure It was examined. In parallel with this, as a comparative test (positive control), the antihypertensive calcium antagonist, diltiazem, was observed to suppress blood pressure increase (Hiroshi Narita, Taku Nagao, Masanori Inazumi, Hitoshi Iwasaki, Takashi Morita: Effects of Diltiazem on SHR blood pressure elevation and associated cardiac hypertrophy and vascular thickening, Japanese Pharmacology Journal 86 (3): 165-174, 1985).

1. In the test animals and rearing conditions test, male SHR / N Crj rats (SPF, Charles River Japan Co., Ltd.), which are commonly used in pharmacological tests as spontaneously hypertensive rats, were used. The animals were obtained at 4 weeks of age (56-76 g body weight), were provided with a quarantine period of 5 days and then a habituation period of 3-4 days, during which no abnormalities were used in the study. The body weight range at the start of administration was 96-120 g.

  Animals have a temperature of 20-26 ° C (actual value: temperature 20-23 ° C), humidity 40-70% (actual value: humidity 43-65%), light and darkness 12 hours each (lighting: 6 am-6 pm), The animals were raised in an animal room maintained at a ventilation rate of 12 times / hour (fresh air sterilized by a filter). Blood pressure was measured in a soundproof room.

  The animals were individually housed using stainless steel five-cage cages (W: 755 × D: 210 × H: 170 mm). The feed was a solid feed (CRF-1, Oriental Yeast Co., Ltd.) within 5 months after production, and tap water was freely consumed.

  During the test, the test animals were divided into three groups (each group, 10 animals): a control group (administration with water for injection), a purple corn extract administration group, and a diltiazem administration group (positive control group). In addition, after grouping the body weight and systolic blood pressure by layer using a computer, the starting date of administration was such that the average body weight and average systolic blood pressure of each group and their variance were approximately equal by random sampling. Went to.

2. Test Method (1) Administration Sample and Administration Method The purple corn extract used was prepared by the method described in the above Preparation Example. Further, diltiazem hydrochloride (manufactured by Wako Pure Chemical Industries, Ltd.) was used as diltiazem which is a positive control substance. These samples were used after being dissolved in water for injection (manufactured by Otsuka Pharmaceutical Co., Ltd.) at a predetermined concentration after weighing the required amount. In the control group, this water for injection (manufactured by Otsuka Pharmaceutical Factory) was used as the administration liquid.

  The number of administrations is twice a day in the morning and afternoon, and each dose is 28.35 mg / kg / dose (daily dose, 56.7 per dose) based on the body weight measured immediately before administration. mg / kg / day), diltiazem is Yoshida et al. (Masumi Yoshida et al .: Pharmacokinetic study of medicinal herb formulation-effect on blood pressure increase in SHR, pharmacology and treatment 19 (9): 3651-3656, 1991) and Narita et al. (Hiroshi Narita et al .: Effect of Diltiazem on SHR elevation of blood pressure and associated cardiac hypertrophy and vascular hypertrophy, and reports on suppression of blood pressure elevation with reference to the report of Japanese Pharmacology Journal 86 (3): 165-174, 1985) 60 mg / kg / dose (daily dose, 120 mg / kg / day). Also. Administration was oral administration, and forced oral administration was performed using a disposable syringe made of polypropylene equipped with an oral sonde for rats. The administration was performed once each in the morning and afternoon on the 8th, 15th, 22nd, 29th, and 36th, with the grouping date as the first day (1st).

(2) General condition observation and body weight measurement For each test animal (10 animals in each group) of each group (control group, purple corn extract administration group, diltiazem administration group), administration day (grouping date), 8 General conditions were observed and body weights were measured prior to morning administration on days 15, 22, 29 and 36.

(3) Measurement of blood pressure and heart rate For each test animal (10 animals in each group) of each group (control group, purple corn extract administration group, diltiazem administration group), 8 Blood pressure measurements were taken on days 15, 22, 29 and 36. The blood pressure during the administration period was measured from about 1 hour after the morning administration to before the afternoon administration. For blood pressure, tail arteriovenous pressure was measured using a non-invasive automatic blood pressure measuring device (BP-98A, Softron Co., Ltd.) and tail caff method without anesthesia, and systolic blood pressure, mean blood pressure, Heart rate was measured. The measurement was carried out three times, and the average value was taken as the measurement value for each individual. In addition, before blood pressure measurement, in order to raise the body temperature of an animal, the animal was put into the heat insulation box (setting temperature: 38 degreeC) for about 5 minutes.

3. Test results (1) General condition and body weight The body weight transition of each group (control group, purple corn extract administration group, diltiazem administration group) is shown in FIG. As can be seen from the figure, during the administration period, no change in general condition or change in body weight was noted in any of the administration groups, indicating a smooth change in body weight.

(2) Blood pressure and heart rate
2.1. Systolic blood pressure Figure 2 shows the results of measuring systolic blood pressure. As can be seen from the figure, the mean value of the systolic blood pressure of the control group (-o-) showed 121 mmHg before the start of administration, but thereafter increased with aging, and showed 206 mmHg on the 36th day of administration. In the purple corn extract administration group (-□-), a significantly lower value was observed compared to the control group from the 8th day of administration, and the increase was significantly suppressed. Moreover, the rise was similarly suppressed also in the diltiazem administration group (-(DELTA)-) of the positive control substance. The inhibitory effect of diltiazem was slightly stronger than that of purple corn extract, and a significantly lower value was observed on day 22 of administration compared to the corn extract administration group.

2.2. Average Blood Pressure and Diastolic Blood Pressure The measurement results of average blood pressure are shown in FIG. 3, and the measurement results of diastolic blood pressure are shown in FIG. As can be seen from FIG. 3, the average value of the average blood pressure of the control group (− ◯ −) showed 97 mmHg before the start of administration, but thereafter increased with aging and showed 171 mmHg on the 36th day of administration. In the purple corn extract administration group (-□-), a significantly lower value was observed compared to the control group from the 8th day of administration, and the increase was significantly suppressed. Moreover, the rise was similarly suppressed also in the diltiazem administration group (-(DELTA)-) of the positive control substance. The inhibitory effect of diltiazem was slightly stronger than that of the purple corn extract, and a significantly lower value was observed on the 8th day of administration compared with the purple corn pigment administration group.

  As can be seen from FIG. 4, the mean value of the diastolic blood pressure of the control group (− ○ −) showed 85 mmHg before the start of administration, but thereafter increased with aging and showed 153 mmHg on the 36th day of administration. . In the purple corn extract-administered group (-□-), a significantly low value was observed on the 8th to 29th days compared with the control group, and the increase was significantly suppressed. Moreover, the rise was similarly suppressed also in the diltiazem administration group (-(DELTA)-) of the positive control substance.

2.3 Change in heart rate Figure 5 shows the results of heart rate measurement. The average value of the heart rate of the control group (-o-) showed 456 beat / min before the start of administration, but thereafter decreased with aging, and showed 394 beat / min on the 36th day of administration. The purple corn extract-administered group (-□-) and the diltiazem-administered group (-Δ-) showed almost the same transition as the control group, and no significant change was observed compared to the control group.

4). Discussion This time, diltiazem used as a positive control substance is a calcium antagonist with antihypertensive action. Narita et al. (Hiroshi Narita et al .: Effects of Diltiazem on SHR blood pressure elevation and associated cardiac hypertrophy and vascular thickening, Japanese Pharmacology Journal 86 (3): 165-174, 1985) are spontaneously hypertensive rats (SHR rats). It has been reported that diltiazem was administered for 4 to 12 weeks after birth, and as a result, the increase in blood pressure of SHR rats was significantly suppressed, but the heart rate was not different from the control group. In this study, diltiazem showed antihypertensive activity but did not affect the heart rate, and the same result as the above report was obtained.

  The purple corn extract used in the present invention has a moderate effect, but, like diltiazem, suppresses all increases in systolic blood pressure, mean blood pressure and diastolic blood pressure. showed that. Furthermore, no adverse effects on heart rate, weight, etc. were observed by the administration of purple corn extract.

  From these results, it became clear that purple corn extract exhibits a blood pressure increase inhibitory effect on subjects who tend to develop hypertension or subjects who tend to develop hypertension. The anti-hypertensive effect of purple corn extract was milder than that of diltiazem, an antihypertensive agent (medicine), and there was no adverse effect on the body. It is thought that it is suitable for.

Food composition (1)
A beverage containing grape juice 20% was prepared using the dark red powder (purple corn extract) prepared in Preparation Example 1 as an antihypertensive agent. Specifically, the ingredients were mixed according to the following formulation, filtered, filled into a 250 ml bottle, sterilized at 80 ° C. for 10 minutes to prepare a beverage containing grape juice 20%.

Sucralose 0.0136 (kg)
5x concentrated grape clear juice 4.0
Citric acid (crystal) 0.25
Purple corn extract 0.20
Grape flavor 0.10
Fruit flavor 0.10
Shimizu appropriate amount
Total 100.00 kg.

Food composition (2)
A non-sugar candy was prepared using the dark red powder (purple corn extract) prepared in Preparation Example 1 as an antihypertensive agent. Specifically, the materials were mixed according to the following formulation, heated and dissolved, and then molded to prepare a non-sugar candy.

Reduced palatinose 60.00 (kg)
Reduced starch saccharified 59.33
Sucralose 0.03
Citric acid (anhydrous) 1.50
Trisodium citrate 0.07
Purple corn extract 10.00
Grape flavor 0.20
Shimizu 30.00
Boiled, yield about 100.00.

Food composition (3)
A drink jelly was prepared using the dark red powder (purple corn extract) prepared in Preparation Example 1 as an antihypertensive agent. Specifically, the materials were mixed according to the following formulation, dissolved by heating, filled into a container, and sterilized at 85 ° C. for 30 minutes to prepare a drink jelly.

Sugar 5.00
Fructose glucose liquid sugar 15.00
5x concentrated white grape juice 4.00
Gelling agent (thickening polysaccharide) 0.20
Gelling agent (gellan gum) 0.15
Trisodium citrate 0.10
Calcium lactate 0.10
Citric acid (anhydrous) 0.18
Purple corn extract 0.33
Grape flavor 0.30
Shimizu appropriate amount
Total 100.00 kg.

Food composition (4)
Using the dark red powder (purple corn extract) prepared in Preparation Example 1 as an antihypertensive agent, the materials were mixed according to the following formulation, and tablets were prepared using a tableting machine.

Sorbitol 79.75 (kg)
Sucrose fatty acid ester 0.15
Fragrance 0.1
Purple corn extract 20.0
Total 100.0 kg.

For each group [control group (-○-), purple corn extract administration group (-□-), and diltiazem administration group (positive control group) (-Δ-)] It is a figure shown experimentally (Test Example 1). In Test Example 1, each group [control group (-○-), purple corn extract administration group (-□-), and diltiazem administration group (positive control group) (-Δ-)] was measured after administration of each sample. It is a figure which shows the result of the performed systolic blood pressure. In the figure, * indicates a significant difference from the control group P <0.05, ** indicates a significant difference from the control group P <0.01, and # indicates a significant difference from the purple corn extract administration group P <0.05. This is shown (the same applies to FIGS. 3 to 5). In Test Example 1, each group [control group (-○-), purple corn extract administration group (-□-), and diltiazem administration group (positive control group) (-Δ-)] was measured after administration of each sample. It is a figure which shows the average value of the measured blood pressure. In Test Example 1, each group [control group (-○-), purple corn extract administration group (-□-), and diltiazem administration group (positive control group) (-Δ-)] was measured after administration of each sample. It is a figure which shows the result of the diastolic blood pressure. In Test Example 1, each group [control group (-○-), purple corn extract administration group (-□-), and diltiazem administration group (positive control group) (-Δ-)] was measured after administration of each sample. It is a figure which shows the measured heart rate.

Claims (3)

An antihypertensive composition comprising an aqueous extract of purple corn as an active ingredient. The antihypertensive composition according to claim 1, which is used by being added to food. A health food containing an aqueous extract of purple corn used for the prevention, treatment or amelioration of hypertension.

Images